+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Late Phase Study Trends and Market Outlook (2016-2020)

  • ID: 4227021
  • Report
  • July 2016
  • Region: Global
  • 71 Pages
  • Industry Standard Research (ISR)
1 of 2

In much of our research, we make a point to ask respondents for their outlook on market changes or trends they expect to occur regarding a specific topic. Keeping an eye on what is coming down the pike is critical to ensure the industry isn’t moving forward without you. No one wants to be left in the dust…which can happen quickly in the ever-changing pharmaceutical industry.  To this end, ISR dedicated a research effort to providing a broad view into the industry’s perspectives on the clinical development market.  For this report, 102 Late Phase decision-makers were surveyed to gather their insights into where the Late Phase market is expected to head over the next four years.

What you Will Learn:

  • 4-year examination of the industry’s Late Phase market dynamics, such as study volume and outsourced spend, analyzed by study design (Interventional studies and Observational research) and by study type (Post-marketing Safety studies, Health Economics and Outcomes Research, and Expanded Access studies)
  • Average dollar value of outsourced Late Phase studies and how this varies by sponsor size
  • Criteria sponsors use to select (and disqualify) clinical service providers
  • Current and future predictions for Late Phase trends, including use of technology, study complexity, and reliance on EMRs

How You Can Use This Report:

  • Gain understanding of the key decision-makers within sponsor organizations to develop more targeted communications
  • Learn the most desirable characteristics of a Late Phase
  • service provider
  • Discover trends in Late Phase technology use
Note: Product cover images may vary from those shown
2 of 2

1. Introduction

2. Methodology
3. Respondent Demographics & Qualifications 

  • Participant Geography
  • Participant Company Size

4. Executive Summary 

  • Market Dynamics
  • Mean Late Phase spend by study design
  • Median Late Phase spend by study design
  • Outsourced proportion of Late Phase spend by study design-past 12 months
  • Mean Late Phase spend by study category
  • Change in Late Phase spend by study type
  • Late Phase trends
  • Provider Perceptions and Selection
  • Outsourcing decision-making
  • Number of preferred providers
  • Difficulty using non-preferred providers
  • Late Phase service provider selection drivers
  • Most important selection drivers by study category
  • Desired provider characteristics
  • Reasons providers lose bids
  • CRO performance satisfaction drivers

5. Study Data

  • Market Dynamics
    • Market dynamics by study design
    • Market dynamics by study category
    • Change in Late Phase spend by study type
    • Change in outsourced Late Phase spend by study type
    • Data sources allocation
    • Emerging markets for Late Phase studies
  • Provider Perceptions and Selection
    • Service provider familiarity
    • Number of preferred providers
    • Difficulty using non-preferred providers
    • Service provider use
    • Service provider preference
    • Desired provider characteristics
    • Provider selection attributes for Expanded Access studies
    • Provider selection attributes for Post-marketing
    • Safety studies
    • Provider selection attributes for HEOR studies
    • Reasons providers lose bids
    • Decision-making influence: Designing the Late Phase study
    • Decision-making influence: Deciding whether to outsource study
    • Decision-making influence: Holding the budget for study conduct
    • Decision-making influence: Deciding which CROs to invite to bid
    • Decision-making influence: Making the final CRO Selection
    • Decision-making influence: Directly managing the
    • CRO delivery
    • CRO performance satisfaction drivers
  • Late Phase Trends
    • Importance of technology
    • Study complexity
    • Global nature
    • Use of Electronic Medical Records (EMR)
    • Use of existing data sources

6. Respondent Demographics

  • Company type
  • Areas of responsibility
  • Drug development responsibilities
  • Respondent location
  • Job title
  • Recent outsourcing involvement
  • Drug development involvement
  • Drug development involvement by phase
Note: Product cover images may vary from those shown
3 of 2